| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_116c851e729089df9a427027272fa290 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-715
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 |
| filingDate |
2012-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_efd8486ed270effd294eed3434e078b2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f876828e68716b0cfcec4d47fa476f7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f78b17d292a471794537cb60af36192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b4cf0a9a8780168d465c5d743bd9e289 |
| publicationDate |
2013-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-201309304-A |
| titleOfInvention |
Treatment of pulmonary embolism and biotinylated idrabiparin for secondary prevention of venous thromboembolism (IDRABIOTAPARINUX) |
| abstract |
The present invention relates to the use of biotinylated idrabiotaparinux for the treatment of pulmonary embolism in patients with or without deep venous thrombosis and for venous thromboembolism in such patients Secondary prevention, wherein the efficacy and safety of such uses are clinically proven by Phase III clinical trials. |
| priorityDate |
2011-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |